Brazil Submissions
Brazil Submissions : Brazil is the largest pharmaceutical market in Latin America and ranks sixth globally, making entry into this market a strategic priority. However, Brazil’s national regulatory authority — the Agência Nacional de Vigilância Sanitária (ANVISA) — maintains a strict and technically complex approval process. In this guide, we break down how to successfully register your drug with ANVISA,
-
Drug Categories and Initial Requirements
- Before initiating the submission, companies must:
- Identify the correct classification for their product.
- Designate a local Brazilian legal representative, who is responsible for registration, importation, and regulatory communication.
- Verify reference drugs for generic and similar submissions to ensure pharmaceutical equivalence.
ANVISA classifies drugs into categories such as new drugs, generics, branded generics (similar medicines), herbal, biologicals, OTCs, and radiopharmaceuticals. Each has its own set of regulatory and data requirements.
-
CTD Format: Brazil’s Regulatory Standard
Since 2019, ANVISA has adopted the international Common Technical Document (CTD) format, structured into:
- Module 1: Regional administrative information (licenses, powers of attorney, product labeling in Portuguese).
- Modules 2 to 5: Quality (CMC), non-clinical, and clinical data per ICH M4.
In 2024, ANVISA confirmed that all new and variation filings must be submitted electronically, with a declaration that the complete CTD will be submitted via USB or physical media (“Aditamento – Formato CTD”). This hybrid model remains valid until April 30, 2025, after which full electronic submission is expected to be mandatory.
-
Regulatory Filing Process Step-by-Step
- Module 1: Power of attorney, GMP certificates, Certificate of Pharmaceutical Product (CPP), local labeling, safety data, and international regulatory status.
- Module 2: Executive summaries of quality, safety, and efficacy.
- Module 3: Comprehensive quality data (drug substance, manufacturing, specifications, stability).
- Modules 4 & 5: Non-clinical (toxicology) and clinical (bioequivalence, PK, efficacy) studies.
- An initial electronic petition is submitted through ANVISA’s portal, accompanied by a declaration about submitting the full CTD in physical format.
- The CTD Aditamento (full technical file) is delivered manually to ANVISA via USB or DVD.
- New drug: 120 days
- Post-approval changes: 60 days
- Priority reviews: 45 days
- ANVISA may inspect API and FDF manufacturing sites. These usually happen within 6 months post-submission, and GMP certificates are issued in 45–60 days.
- Samples may be requested for testing in accredited Brazilian labs to ensure compliance with submitted specs.
- Once the technical review, GMP inspection, and sample testing are complete, ANVISA grants market authorization, valid for 10 years.
- Renewals must be submitted 6 months before expiration.
- Gap Analysis: We evaluate your dossier and processes against ANVISA’s expectations for CTD, GMP, and stability.
- CTD Preparation: We prepare and format Modules 1–5, ensuring accuracy, compliance, and smooth navigation through the e-submission process.
- Stability Strategy & FDS: We design and support studies compliant with Zone IVB and forced degradation requirements.
- Submission Management: We handle hybrid protocol logistics, from electronic petitions to physical media delivery.
- GMP Audit Readiness: We offer mock inspections, training, and remediation strategies to prepare for ANVISA site audits.
- Regulatory Interactions: We prepare response packages for DQRs and guide your communication with ANVISA.
- Post-approval Services: We manage renewals, label updates, and change control (post-approval variations).
(i)Dossier Preparation
Key sections include:
Brazil requires Zone IVB stability studies (hot/humid climate): minimum 6 months accelerated + 6 months long-term to justify a 24-month shelf life. Forced degradation studies (FDS) are also mandatory.
(ii)Submission and Protocol
(iii)Technical Review
ANVISA reviews the submission and may issue a deficiency letter (DQR). Target timelines are:
The review clock pauses until the applicant responds to queries.
(iv)GMP Inspections
(v)Local Testing
(vi)Registration Approval
Any changes (site, composition, packaging) require post-approval filings known as “secondary petitions” with defined review timelines.
How Masuu Can Help You
Masuu Pharma Quality and Regulatory Consultants offers end-to-end support for Brazilian regulatory filings(Brazil Submissions). Our services include:Frequently Asked Questions
Brazil pharmaceutical submissions are regulatory applications submitted to ANVISA (Agência Nacional de Vigilância Sanitária) for the registration and approval of medicinal products in Brazil. The requirements vary depending on whether the product is a new drug, generic, similar medicine, biological, herbal, OTC, or radiopharmaceutical.
Companies must first determine the appropriate product classification and regulatory pathway. They also need a local Brazilian legal representative to support registration, importation, and regulatory communication, while generic and similar products require appropriate reference-drug verification.
ANVISA uses the Common Technical Document (CTD) structure for pharmaceutical submissions. Module 1 contains regional administrative information, while Modules 2–5 cover quality, non-clinical, and clinical information in alignment with the international CTD framework.
The dossier can include powers of attorney, GMP certificates, CPP, Portuguese labeling, regulatory status, quality summaries, manufacturing and stability information, toxicology data, bioequivalence studies, pharmacokinetic data, and clinical evidence. Masuu Global can support preparation and organization of Modules 1–5.
Brazil’s climatic conditions make stability strategy an important part of pharmaceutical submissions. The supplied requirements include Zone IVB stability studies, accelerated and long-term studies, as well as forced degradation studies (FDS), to support product quality and proposed shelf life.
The filing process can involve an electronic petition through the ANVISA portal together with the required CTD documentation and declarations. Depending on the applicable submission requirements and transition arrangements, additional technical documentation may need to be provided through the prescribed submission pathway.
ANVISA conducts a technical assessment of the submitted quality, safety, and efficacy information and may issue deficiency or query letters requiring additional information. The review timeline depends on the application type and applicable regulatory pathway, and the review clock may be affected while responses are being evaluated.
ANVISA may conduct GMP inspections of API and finished-product manufacturing facilities as part of the regulatory process. Masuu Global can support companies through mock inspections, GMP gap assessments, training, and remediation activities to improve inspection readiness.
Yes. Depending on the product and regulatory pathway, ANVISA may request samples for testing through appropriate accredited laboratories. Masuu Global can help clients prepare the necessary documentation and coordinate regulatory requirements associated with sample testing.
Following completion of the applicable technical review, GMP assessment, and other regulatory requirements, ANVISA may grant marketing authorization. Companies must continue managing lifecycle obligations, including renewals, labeling updates, site changes, composition changes, packaging changes, and other applicable post-approval variations.
Masuu Global provides end-to-end Brazil submission support, including gap analysis, CTD preparation, stability and FDS strategy, submission management, GMP audit readiness, regulatory interactions, and post-approval support. Our team helps companies prepare their documentation and navigate ANVISA requirements efficiently.
Yes. Masuu Global supports preparation of responses to ANVISA deficiency or query letters and assists with regulatory communication throughout the review process. We also support renewals, labeling updates, change control, and post-approval variations to help maintain ongoing compliance in Brazil.
